Recs

1

Biotech Winners: Pernix, Myriad, Repros, OraSure

In this video from Thursday's Market Checkup, Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today.

In this segment, a look at some big winners during the past two days in the biotech space. Pernix (NASDAQ: PTX  ) saw a nearly 70% pop upward yesterday as the company settled a few housekeeping items, including hiring a new CEO, settling a pending legal matter, and securing $65 million in funding, a lifesaver compared to its cash-on-hand situation prior to this. Myriad Genetics (NASDAQ: MYGN  ) , maker of a test for breast cancer, is up 15% after its fiscal second-quarter net income soared by 43.7%, to $50.4 million, with sales increasing $55 million, to $204.1 million. Repros Therapeutics (NASDAQ: RPRX  ) is up 15% after positive meetings with the FDA over Androxal, its testosterone replacement drug. The company now believes it will not have to run any additional safety studies, and will be able to file for approval this year, which had investors cheering. And OraSure (NASDAQ: OSUR  ) is up 10% after reporting strong earnings, with revenue coming in at $28.8 million, which was a 30% improvement and a solid beat.

So what's the best way for investors to play the high-risk, high-reward biotech space?
The best way to play the biotech space is to find companies that shun the status quo and, instead, discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report, "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2827988, ~/Articles/ArticleHandler.aspx, 7/7/2015 10:23:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson
TMFGreenwave

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 1 hour ago Sponsored by:
DOW 17,776.91 93.33 0.53%
S&P 500 2,081.34 12.58 0.61%
NASD 4,997.46 5.52 0.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/7/2015 3:59 PM
MYGN $34.85 Up +0.88 +2.59%
Myriad Genetics CAPS Rating: ***
OSUR $5.19 Up +0.27 +5.49%
OraSure Technologi… CAPS Rating: *
PTX $5.63 Down -0.22 -3.76%
Pernix Therapeutic… CAPS Rating: No stars
RPRX $7.14 Down -0.08 -1.11%
Repros Therapeutic… CAPS Rating: *

Advertisement